Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

3 terminated/withdrawn out of 12 trials

Success Rate

72.7%

-13.8% vs industry average

Late-Stage Pipeline

17%

2 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

N/A

2(25.0%)

Phase 3

1(12.5%)

Phase 4

1(12.5%)

8Total

Phase 2(4)

N/A(2)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT01454154Phase 2Completed

Glyburide (RP-1127) for Traumatic Brain Injury (TBI)

Role: collaborator

NCT01339689Phase 2Completed

Ganaxolone in Posttraumatic Stress Disorder (PTSD)

Role: collaborator

NCT01517711Phase 4Completed

Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)

Role: lead

NCT01625962Completed

Brain Indices of Risk for Posttraumatic Stress Disorder (PTSD) After Mild Traumatic Brain Injury (mTBI)

Role: lead

NCT01387490Not ApplicableCompleted

CONcussion Treatment After Combat Trauma (CONTACT)

Role: lead

NCT01554891Completed

INTRuST Structured Assessment For Evaluation of TBI (SAFE-TBI)

Role: lead

NCT01419223Completed

Patient Participation Beliefs and Post-Traumatic Stress Disorder (PTSD)

Role: lead

NCT01650220Terminated

Cardiovascular Risk Markers in Veterans With Post Traumatic Stress Disorder

Role: lead

NCT01212848Phase 3Unknown

Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation

Role: lead

NCT01418976Not ApplicableCompleted

Walking and Balance Post-TBI

Role: lead

NCT01416948Phase 2Terminated

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

Role: lead

NCT01626131Phase 2Terminated

Exercise: A Novel Treatment for Combat Post Traumatic Stress Disorder

Role: lead

All 12 trials loaded